Medical Hypotheses
Volume 57, Issue 2 , Pages 135-138 , August 2001

Sphingomyelin: a natural modulator of membrane homeostasis and inflammation

Received 26 September 2000 ,Accepted 17 January 2001.

References 

    REFERENCES
  1. Barenholz, Y. Sphingomyelin-lecithin balance in membranes: Composition, structure, and function relationships. Shinitzky, M. editor. Physiology of Membrane Fluidity, Boca Raton, CRC press, 1984, 131, 173.
  2. Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem. 1994;269:3125–3128
  3. Thomas CE, Packer L, Cadenas E. Approaches and rationale for the design of synthetic antioxidants as therapeutic agents. Handbook of synthetic antioxidants. New York: Marcel Dekker;; 1997; p. 1–52
  4. Subbaiah PV, Subramanian VS, Wang K. Novel physiological function of sphingomyelin in plasma – Inhibition of lipid peroxidation in low density lipoproteins. J Biol Chem. 1999;274:36409–36414
  5. Parthasarathy S, Steinbrecher UP, Barnett J, Witztum JL, Steinberg D. Essential role of phospholipase A2activity in endothelial cell-induced modification of low density lipoprotein. Proc Natl Acad Sci USA. 1985;82:3000–3004
  6. Leitinger N, Watson AD, Hama SY, Ivandic B, Qiao JH, Huber J. Role of group II secretory phospholipase A2in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. Arteriosclerosis, Thrombosis & Vascular Biology. 1999;19:1291–1298
  7. Subbaiah PV, Liu M. Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecithin-cholesterol acyltransferase. J Biol Chem. 1993;268:20156–20163
  8. Bolin DJ, Jonas A. Sphingomyelin inhibits the lecithin-cholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding. J Biol Chem. 1996;271:19152–19158
  9. Lobo LIB, Wilton DC. Combined effects of sphingomyelin and cholesterol on the hydrolysis of emulsion particle triolein by lipoprotein lipase. Biochim Biophys Acta. 1997;1349:122–130
  10. Koumanov K, Wolf C, Bereziat G. Modulation of human type II secretory phospholipase A2by sphingomyelin and annexin VI. Biochem J. 1997;326:227–233
  11. Dawson RM, Hemington N, Irvine RF. The inhibition of diacylglycerol-stimulated intracellular phospholipases by phospholipids with a phosphocholine-containing polar group. A possible physiological role for sphingomyelin. Biochem J. 1985;230:61–68
  12. Kim MY, Linardic C, Obeid L, Hannun Y. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. J Biol Chem. 1991;266:484–489
  13. Fujimoto Y, Sakuma S, Tsunomori M, Sumiya T, Fujita T. Sphingomyelin inhibits platelet 12- lipoxygenase activity. Eur J Pharmacol. 1999;378:233–236

PII: S0306-9877(01)91336-2

doi: 10.1054/mehy.2001.1336

Medical Hypotheses
Volume 57, Issue 2 , Pages 135-138 , August 2001

Article Tools